Steroidogenesis of cultured granulosa cells in women at risk for ovarian hyperstimulation syndrome.
OBJECTIVE
To determine if cultured human granulosa cells (GCs) obtained from women at risk for ovarian hyperstimulation syndrome (OHSS) possess altered steroidogenic capacity.


METHODS
Prospective analysis of 28 consecutive in vitro fertilization-gamete intrafallopian transfer (IVF-GIFT) cycles.


METHODS
In Vitro Fertilization Program at Rush Presbyterian St. Luke's Medical Center in Chicago, Illinois.


METHODS
Eighteen patients (group I) with serum estradiol (E2) levels > 7,342 pmol/L on the day of exogenous human chorionic gonadotropin (hCG) administration (day 0) with > 10 ovarian follicles present (high risk for OHSS); 10 patients (group II) with E2 < or = 7,342 pmol/L on day 0 and < or = 10 follicles.


METHODS
Human GCs obtained during gonadotropin-releasing hormone agonist-pretreated IVF-GIFT cycles were cultured in the absence (control) or presence (hCG) of hCG, 1 IU/mL, and/or androstenedione (A) 10(-7) M. Granulosa cells obtained from follicles < or = 15 mm diameter were cultured separately from those obtained from follicles > 15 mm diameter.


METHODS
Estradiol (E2) and progesterone were measured in tissue-culture medium by a solid-phase direct radioimmunoassay.


RESULTS
In vitro E2 production by cultured GCs was significantly increased in follicles < or = 15 mm diameter from women considered at risk of developing OHSS (group I). Estradiol response to hCG and/or A appeared enhanced in all follicles in group I. Progesterone production in the basal and hCG challenged state was greater in cells obtained from large follicles in group I than in group II.


CONCLUSIONS
Ovarian hyperstimulation syndrome appears to be a function of an increased number of follicles that express an enhanced steroidogenic capacity.
Leya
J M
JM
Department of Obstetrics and Gynecology, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois.
Rawlins
R G
RG
Radwanska
E
E
Beckmann
M W
MW
D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004958:Estradiol / Q000096:biosynthesis*; D005260:Female; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000378:metabolism; D015181:Gamete Intrafallopian Transfer; D006107:Granulosa Cells / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology; D016471:Ovarian Hyperstimulation Syndrome / Q000378:metabolism*; D011374:Progesterone / Q000096:biosynthesis*; D011446:Prospective Studies; D012307:Risk Factors
D006063:Chorionic Gonadotropin; D011374:Progesterone; D004958:Estradiol; D016729:Leuprolide